The age of enlightenment in melanoma immunotherapy
Abstract An updated survival analysis by Callahan et al. published in the February 1, 2018 issue of the Journal of Clinical Oncology reported a 3-year overall survival (OS) rate of 63% for 94 patients with previously treated or untreated advanced melanoma who received ipilimumab and nivolumab as con...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2018-08-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40425-018-0397-8 |